Search - tctmd.com

Displaying 1 - 20 of 59

Sort: Relevancy | Date

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Michael O'Riordan

March 04, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Daily News

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

Todd Neale

October 02, 2024

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

FDA Approves TriClip TEER Device for Tricuspid Repair

L.A. McKeown

April 02, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

FDA Approves a Second Pulsed-Field Ablation System

Todd Neale

January 31, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

L.A. McKeown

September 23, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

Caitlin E. Cox

December 29, 2021

Advertisement

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Coverage and Use of Impella and Watchman: A Tale of Four Countries

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

Little Pre- and Postmarket Testing for Most Recalled CV Devices

June 2024 Dispatch for the CV Team

FDA Approves Bioresorbable Scaffold for BTK Lesions

FDA Approves TriClip TEER Device for Tricuspid Repair

Bempedoic Acid Gains CV Risk Reduction Indication

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

FDA Approves a Second Pulsed-Field Ablation System

TCTMD’s Top 10 Most Popular Stories for December 2023

FDA Approves Colchicine for Decreasing CV Events

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Most Patient-Reported Outcome Measures in CVD Fall Short

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

TCTMD’s Top 10 Most Popular Stories for December 2021

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content